Mode
Text Size
Log in / Sign up

Thyroid-associated ophthalmopathy

Part of Graves' disease

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for thyroid-associated ophthalmopathy

4 trials tracked for thyroid-associated ophthalmopathy: 2 in phase 3 or 4.

4Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 2
  1. Phase 4 Rituximab (RTX) Therapy in Patients With Active TAO Completed
  2. Phase 3 Trial of Rituximab for Graves' Ophthalmopathy Completed
  3. Phase 2 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Completed
  4. Phase 2 A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Graves' disease

Related studies from across the Graves' disease family.